HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study

Abroad (travel likely)RecruitingPHASE3

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

The First People's Hospital of Foshan, Foshan, Guangdong, China
Contact: Study coordinator (HuanWei Chen) · 1547463629@qq.com · 15626470388
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Ming Shi, MD) · shiming@mail.sysu.edu.cn · 8620-87343115
Guangzhou Twelfth People 's Hospita, Guangzhou, Guangdong, China
Contact: Study coordinator (Yuanmin Zhou, MD) · 13430288977@139.com · 15521278919
Contact: Principal Investigator (YuanMin Zhou, MD)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC

Hepatocellular Carcinoma · Beyond Milan Criteria

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC

Hepatocellular Carcinoma (HCC) · Radiotherapy, Adjuvant · Immune Checkpoint Inhibitor

Abroad (travel likely)RecruitingPHASE3

Beijing, China

Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE3

Nanchang, China · Chifeng, China

Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC

Hepatocellular Carcinoma Non-resectable

Abroad (travel likely)RecruitingPHASE3

Guangzhou, China